



Otarmeni™ Gene Therapy Treatment Centers

ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions. Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Otarmeni** (lunsotogene parvec-cwha) which is approved to treat **Otoferlin (OTOF) gene-related hearing loss**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
California	San Diego	Rady Children's Hospital San Diego
Massachusetts	Boston	Boston Children's Hospital
Ohio	Cincinnati	Cincinnati Children's Hospital Medical Center
Wisconsin	Milwaukee	Children's Hospital of Wisconsin